BeyondSpring (BYSI)
(Delayed Data from NSDQ)
$1.91 USD
+0.11 (6.11%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $1.88 -0.03 (-1.57%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BYSI 1.91 +0.11(6.11%)
Will BYSI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BYSI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BYSI
Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates
Humanigen Inc. (HGEN) Reports Q2 Loss, Lags Revenue Estimates
BYSI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates
Codexis (CDXS) Surges 9.7%: Is This an Indication of Further Gains?
VistaGen Therapeutics, Inc. (VTGN) Reports Q4 Loss, Misses Revenue Estimates
Other News for BYSI
iBio, Mesoblast, Kodiak Sciences among healthcare movers
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
BeyondSpring reports first patient dosed with pembrolizumab, plinabulin plus EP
BeyondSpring Announces Executive Leadership Change
12 Health Care Stocks Moving In Thursday's Intraday Session